J Breast Cancer.
2012 Mar;15(1):24-33. 10.4048/jbc.2012.15.1.24.
Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status
- Affiliations
-
- 1Department of Pathology, Yeungnam University College of Medicine, Daegu, Korea. ykbae@ynu.ac.kr
- 2Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
- 3Department of Surgery, Yeungnam University College of Medicine, Daegu, Korea.
- 4Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
- KMID: 2286470
- DOI: http://doi.org/10.4048/jbc.2012.15.1.24
Abstract
- PURPOSE
This study aimed to investigate the clinical significance of chromosome 17 centromere (CEP17) multiplication (increased copy number of CEP17) related to human epidermal growth factor receptor 2 (HER2) and topoisomerase II alpha (TOP2A) status in patients with invasive breast cancer.
METHODS
We constructed tissue microarrays using 594 invasive breast cancer samples and performed single-color silver-enhanced in situ hybridization (SISH) assay for HER2, TOP2A, and CEP17 to assess for copy number aberrations. The association of CEP17 multiplication with patient survival was analyzed according to HER2 and TOP2A status.
RESULTS
Among 567 informative cases, HER2 amplification was noted in 22.8%, TOP2A amplification in 8.3% and TOP2A deletion in 11.1%. CEP17 multiplication was identified in 33.2% and was significantly associated with worse overall survival (OS) (p=0.02) and disease-free survival (DFS) (p=0.02). CEP17 multiplication correlated with patient survival in patients with normal TOP2A or non-amplified HER2 status, but the prognostic significance was lost in those with altered TOP2A or amplified HER2. On multivariate analyses, CEP17 multiplication was an independent prognostic factor for poorer OS (p=0.02) and DFS (p=0.01) in patients with normal TOP2A and non-amplified HER2.
CONCLUSION
CEP17 multiplication was identified as a promising prognostic marker in patients with invasive breast cancer exhibiting either non-amplified HER2 or normal TOP2A status.
MeSH Terms
-
Antigens, Neoplasm
Breast
Breast Neoplasms
Centromere
Chromosomes, Human, Pair 17
Coat Protein Complex I
Disease-Free Survival
DNA Topoisomerases, Type II
DNA-Binding Proteins
Genes, erbB-2
Humans
In Situ Hybridization
Multivariate Analysis
Prognosis
Receptor, Epidermal Growth Factor
Receptor, erbB-2
Antigens, Neoplasm
Coat Protein Complex I
DNA Topoisomerases, Type II
DNA-Binding Proteins
Receptor, Epidermal Growth Factor
Receptor, erbB-2
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing
- HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
- Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer
- Diagnosis and Treatment of HER2-Positive Breast Cancer
- Expression Profiles of Retinoblastoma Protein and p27Kip1 According to HER2 Amplification Status in Primary Breast Cancer
